Canton Hathaway’s Novo Nordisk NVO Stock Holding History

Canton Hathaway’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,268	Closed	-$183K	–	310
2020 Q3	$183K	Buy	+5,268	New	+$176K	0.08%	107

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

Canton Hathaway's NVO Position: Q4 2020 in Review

Canton Hathaway sold out of Novo Nordisk (NVO) in Q4 2020, closing a stake of 5,268 shares — an estimated $183K sold.

Canton Hathaway first reported a position in NVO in Q3 2020 and held it in 1 quarter. The position peaked at $183K in Q3 2020. 702 funds tracked by Wall St. Rank hold NVO as of Q4 2020.

Canton Hathaway reported no remaining Novo Nordisk position as of Q4 2020 after selling out during the quarter.
Canton Hathaway sold 5,268 Novo Nordisk shares in Q4 2020, an estimated $183K.
Canton Hathaway first reported a position in Novo Nordisk in Q3 2020 and held it in 1 quarter.
Canton Hathaway's Novo Nordisk position peaked at $183K in Q3 2020.
702 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2020.

Based on Canton Hathaway's 13F filing for Q4 2020, filed 3 Feb 2021.